吲哚菁绿清除率预测接受经导管瓣膜介入治疗的重度房室瓣反流患者的结局
该研究分析了2020年8月至2021年5月在慕尼黑大学医院接受经导管瓣膜修复/置换术的重度二尖瓣反流或三尖瓣反流患者的肝功能与结局。结果显示经典血清肝功能指标术后无变化,而LIMON®试验评估的肝功能显著改善(P ≤ 0.001);基线吲哚菁绿血浆消失率<12.95%/min的患者1年死亡率显著增高(HR 1.54,95%CI 1.05-2.25,P=0.027)且纽约心脏协会分级改善较低(P=0.05)。作者认为LIMON®试验可能提供关于患者心肝损伤和预后的实时信息。
要点
- 经典血清肝功能指标在经导管瓣膜介入术后未发生改变。
- LIMON®试验评估的肝功能在术后显著改善(P ≤ 0.001)。
- 基线吲哚菁绿血浆消失率<12.95%/min与1年死亡率增高相关(HR 1.54,95%CI 1.05-2.25,P=0.027)。
核心结论
- LIMON®试验可能提供关于患者心肝损伤和预后的实时信息,尤其在经导管瓣膜治疗前仔细选择患者的背景下。
研究设计与样本
- 研究分析了2020年8月至2021年5月在慕尼黑大学医院接受经导管瓣膜修复/置换术治疗二尖瓣反流或三尖瓣反流的患者,共44例。
主要发现
- 44例患者中,21例(48%)因重度二尖瓣反流治疗,20例(46%)因重度三尖瓣反流治疗,3例(7%)因两者兼有治疗。
- 手术成功(定义为二尖瓣反流/三尖瓣反流≤2+)在二尖瓣反流患者中为94%,在三尖瓣反流患者中为92%。
- 经典血清肝功能参数在经导管瓣膜修复/置换术后未发生变化,而LIMON®试验评估的肝功能显著改善(P ≤ 0.001)。
- 基线吲哚菁绿血浆消失率<12.95%/min的患者1年死亡率显著增高(HR 1.54,95%CI 1.05-2.25,P=0.027),且纽约心脏协会分级改善较低(P=0.05)。
临床怎么用
- 作者认为,在经导管瓣膜治疗前仔细选择患者的背景下,LIMON®试验可能提供关于患者心肝损伤和预后的实时信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Severe mitral regurgitation (MR) and tricuspid regurgitation (TR) aggravate haemodynamic stress leading to congestive heart failure with impaired hepatic function, also known as cardiohepatic syndrome (CHS). Current perioperative risk calculators do not sufficiently consider CHS and serum liver function parameters lack sensitivity to diagnose CHS. Indocyanine green and its elimination (measured by the LIMON® test) represent a dynamic and non-invasive test which correlates with the hepatic function. Nevertheless, its utility in the setting of transcatheter valve repair/replacement (TVR) to predict CHS and outcome remains unknown. METHODS: We analysed liver function and outcomes of patients undergoing TVR for MR or TR between August 2020 and May 2021 at the Munich University Hospital. RESULTS: Out of a total of 44 patients treated at the University Hospital of Munich, 21 (48%) were treated for severe MR, 20 (46%) for severe TR and 3 (7%) for both diseases. Procedural success defined as MR/TR ≤2+ was 94% among MR patients and 92% among TR patients. While classical serum liver function parameters did not change after TVR, there was a significant improvement in liver function as assessed by the LIMON® test (P ≤ 0.001). Patients with baseline indocyanine green plasma disappearance rate <12.95%/min showed significantly increased 1-year mortality (hazard ratio: 1.54, 95% confidence interval: 1.05-2.25, P = 0.027) and lower New York Hear Association class improvement (P = 0.05). CONCLUSIONS: Especially in the context of the recently stressed importance of a careful patient selection prior to the interdisciplinary treatment of valvular heart disease, the LIMON® test may provide further real-time information on the patients' cardiohepatic injury and prognosis.
引用
- Doldi PM, Stolz L, Buech J, et al. Indocyanine green clearance predicts outcome in patients undergoing transcatheter valve intervention for severe atrio-ventricular valve regurgitation. Interdiscip Cardiovasc Thorac Surg. 2023. PMID: 36847676. doi:10.1093/icvts/ivad024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。